N/A
N=19
A Comparison of Non-invasive Ventilation Methods Used to Prevent Endotracheal Intubation Due to Apnea in Very Low Birth Weight Infants
Apnea of Prematurity
Bottom Line
View on ClinicalTrials.gov: NCT03298035 ↗Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcome: Primary: Number of Participants Who Were Intubated — 6; 8 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- NCPAP as mode for apnea prevention (Device); NIPPV as rescue mode for apnea prevention (Device)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- The University of Texas Health Science Center, Houston
- Primary completion
- Dec 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Were Intubated |
6; 8 | — |
| PRIMARY Duration of Intubation |
10.6; 17.5 | — |
| SECONDARY Number of Apneic Events |
3.78; 6.22 | — |
| SECONDARY Number of Participants With Bronchopulmonary Dysplasia (BPD) |
9; 8 | — |
| SECONDARY Number of Participants With Necrotizing Enterocolitis (NEC) |
1; 5 | — |
| SECONDARY Number of Participants With Air Leak Disorders |
0; 0 | — |
| SECONDARY Weight Gain |
— | — |
| SECONDARY Length of Hospital Stay |
136; 149 | — |
| SECONDARY Number of Participants Who Died |
1; 0 | — |
Summary
The purpose of this study is to determine whether nasal intermittent positive pressure ventilation (NIPPV) reduces the need for endotracheal intubation in very low birth weight infants with persistent apnea who fail nasal continuous positive airway pressure (NCPAP).
Eligibility Criteria
Inclusion Criteria
- Infants born at 6cm H2O or whose team is considering intubation due to apnea. Consider clinically significant apnea as 1 or more events treated with bag-mask ventilation or 3 episodes of apnea requiring stimulation within 1 hour.
- Infants on maximum caffeine therapy (10mg/kg/day)
Exclusion Criteria
- Major congenital anomalies including congenital heart disease
Data sourced from ClinicalTrials.gov (NCT03298035). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.